nodes	percent_of_prediction	percent_of_DWPC	metapath
Sibutramine—CYP3A4—Topotecan—ovarian cancer	0.0324	0.354	CbGbCtD
Sibutramine—CYP3A4—Vinorelbine—ovarian cancer	0.0228	0.249	CbGbCtD
Sibutramine—CYP3A4—Paclitaxel—ovarian cancer	0.016	0.175	CbGbCtD
Sibutramine—CYP3A4—Docetaxel—ovarian cancer	0.0116	0.127	CbGbCtD
Sibutramine—CYP3A4—Doxorubicin—ovarian cancer	0.00865	0.0945	CbGbCtD
Sibutramine—SLC6A3—Dopaminergic Neurogenesis—LMX1A—ovarian cancer	0.00142	0.123	CbGpPWpGaD
Sibutramine—SLC6A3—Alpha-synuclein signaling—KLK6—ovarian cancer	0.00139	0.12	CbGpPWpGaD
Sibutramine—SLC6A4—Monoamine Transport—RBL2—ovarian cancer	0.000636	0.0551	CbGpPWpGaD
Sibutramine—SLC6A4—Monoamine Transport—PVRL2—ovarian cancer	0.000578	0.0501	CbGpPWpGaD
Sibutramine—SLC6A4—Synaptic Vesicle Pathway—NSF—ovarian cancer	0.000561	0.0486	CbGpPWpGaD
Sibutramine—SLC6A2—Monoamine Transport—RBL2—ovarian cancer	0.000547	0.0473	CbGpPWpGaD
Sibutramine—SLC6A2—Monoamine Transport—PVRL2—ovarian cancer	0.000497	0.043	CbGpPWpGaD
Sibutramine—SLC6A3—Monoamine Transport—RBL2—ovarian cancer	0.000484	0.0419	CbGpPWpGaD
Sibutramine—Loss of consciousness—Docetaxel—ovarian cancer	0.000442	0.000493	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000441	0.000492	CcSEcCtD
Sibutramine—SLC6A3—Monoamine Transport—PVRL2—ovarian cancer	0.00044	0.0381	CbGpPWpGaD
Sibutramine—Hyperglycaemia—Epirubicin—ovarian cancer	0.000439	0.00049	CcSEcCtD
Sibutramine—Cough—Docetaxel—ovarian cancer	0.000439	0.000489	CcSEcCtD
Sibutramine—Angina pectoris—Doxorubicin—ovarian cancer	0.000439	0.000489	CcSEcCtD
Sibutramine—Insomnia—Paclitaxel—ovarian cancer	0.000438	0.000488	CcSEcCtD
Sibutramine—Pneumonia—Epirubicin—ovarian cancer	0.000437	0.000487	CcSEcCtD
Sibutramine—Convulsion—Docetaxel—ovarian cancer	0.000436	0.000486	CcSEcCtD
Sibutramine—Paraesthesia—Paclitaxel—ovarian cancer	0.000435	0.000485	CcSEcCtD
Sibutramine—Hypertension—Docetaxel—ovarian cancer	0.000434	0.000484	CcSEcCtD
Sibutramine—Bronchitis—Doxorubicin—ovarian cancer	0.000433	0.000483	CcSEcCtD
Sibutramine—Dyspnoea—Paclitaxel—ovarian cancer	0.000432	0.000481	CcSEcCtD
Sibutramine—Somnolence—Paclitaxel—ovarian cancer	0.000431	0.00048	CcSEcCtD
Sibutramine—Myalgia—Docetaxel—ovarian cancer	0.000428	0.000477	CcSEcCtD
Sibutramine—Chest pain—Docetaxel—ovarian cancer	0.000428	0.000477	CcSEcCtD
Sibutramine—Arthralgia—Docetaxel—ovarian cancer	0.000428	0.000477	CcSEcCtD
Sibutramine—Nausea—Vinorelbine—ovarian cancer	0.000428	0.000477	CcSEcCtD
Sibutramine—Renal failure—Epirubicin—ovarian cancer	0.000427	0.000476	CcSEcCtD
Sibutramine—Dyspepsia—Paclitaxel—ovarian cancer	0.000426	0.000475	CcSEcCtD
Sibutramine—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000426	0.000474	CcSEcCtD
Sibutramine—Stomatitis—Epirubicin—ovarian cancer	0.000423	0.000472	CcSEcCtD
Sibutramine—Urinary tract infection—Epirubicin—ovarian cancer	0.000422	0.00047	CcSEcCtD
Sibutramine—Conjunctivitis—Epirubicin—ovarian cancer	0.000422	0.00047	CcSEcCtD
Sibutramine—Dysuria—Doxorubicin—ovarian cancer	0.000421	0.00047	CcSEcCtD
Sibutramine—Decreased appetite—Paclitaxel—ovarian cancer	0.000421	0.000469	CcSEcCtD
Sibutramine—Dry mouth—Docetaxel—ovarian cancer	0.000419	0.000467	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000418	0.000466	CcSEcCtD
Sibutramine—Sweating—Epirubicin—ovarian cancer	0.000416	0.000464	CcSEcCtD
Sibutramine—Pollakiuria—Doxorubicin—ovarian cancer	0.000416	0.000464	CcSEcCtD
Sibutramine—Pain—Paclitaxel—ovarian cancer	0.000414	0.000462	CcSEcCtD
Sibutramine—Constipation—Paclitaxel—ovarian cancer	0.000414	0.000462	CcSEcCtD
Sibutramine—Haematuria—Epirubicin—ovarian cancer	0.000414	0.000461	CcSEcCtD
Sibutramine—Confusional state—Docetaxel—ovarian cancer	0.000414	0.000461	CcSEcCtD
Sibutramine—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000411	0.000458	CcSEcCtD
Sibutramine—Oedema—Docetaxel—ovarian cancer	0.000411	0.000458	CcSEcCtD
Sibutramine—Anaphylactic shock—Docetaxel—ovarian cancer	0.000411	0.000458	CcSEcCtD
Sibutramine—Weight increased—Doxorubicin—ovarian cancer	0.00041	0.000457	CcSEcCtD
Sibutramine—Epistaxis—Epirubicin—ovarian cancer	0.000409	0.000457	CcSEcCtD
Sibutramine—Infection—Docetaxel—ovarian cancer	0.000408	0.000455	CcSEcCtD
Sibutramine—Sinusitis—Epirubicin—ovarian cancer	0.000407	0.000454	CcSEcCtD
Sibutramine—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000406	0.000453	CcSEcCtD
Sibutramine—Pneumonia—Doxorubicin—ovarian cancer	0.000404	0.00045	CcSEcCtD
Sibutramine—Shock—Docetaxel—ovarian cancer	0.000404	0.00045	CcSEcCtD
Sibutramine—Thrombocytopenia—Docetaxel—ovarian cancer	0.000402	0.000448	CcSEcCtD
Sibutramine—Tachycardia—Docetaxel—ovarian cancer	0.000401	0.000447	CcSEcCtD
Sibutramine—Feeling abnormal—Paclitaxel—ovarian cancer	0.000399	0.000445	CcSEcCtD
Sibutramine—Skin disorder—Docetaxel—ovarian cancer	0.000399	0.000445	CcSEcCtD
Sibutramine—Bradycardia—Epirubicin—ovarian cancer	0.000397	0.000442	CcSEcCtD
Sibutramine—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000396	0.000442	CcSEcCtD
Sibutramine—Renal failure—Doxorubicin—ovarian cancer	0.000395	0.00044	CcSEcCtD
Sibutramine—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000394	0.000439	CcSEcCtD
Sibutramine—Haemoglobin—Epirubicin—ovarian cancer	0.000392	0.000437	CcSEcCtD
Sibutramine—Stomatitis—Doxorubicin—ovarian cancer	0.000392	0.000437	CcSEcCtD
Sibutramine—Anorexia—Docetaxel—ovarian cancer	0.000391	0.000436	CcSEcCtD
Sibutramine—Rhinitis—Epirubicin—ovarian cancer	0.000391	0.000436	CcSEcCtD
Sibutramine—Conjunctivitis—Doxorubicin—ovarian cancer	0.00039	0.000435	CcSEcCtD
Sibutramine—Urinary tract infection—Doxorubicin—ovarian cancer	0.00039	0.000435	CcSEcCtD
Sibutramine—Haemorrhage—Epirubicin—ovarian cancer	0.00039	0.000435	CcSEcCtD
Sibutramine—Hypoaesthesia—Epirubicin—ovarian cancer	0.000388	0.000432	CcSEcCtD
Sibutramine—Pharyngitis—Epirubicin—ovarian cancer	0.000387	0.000431	CcSEcCtD
Sibutramine—SLC6A3—Alpha-synuclein signaling—PARK2—ovarian cancer	0.000386	0.0334	CbGpPWpGaD
Sibutramine—Sweating—Doxorubicin—ovarian cancer	0.000385	0.000429	CcSEcCtD
Sibutramine—Urticaria—Paclitaxel—ovarian cancer	0.000385	0.000429	CcSEcCtD
Sibutramine—Oedema peripheral—Epirubicin—ovarian cancer	0.000384	0.000428	CcSEcCtD
Sibutramine—Hypotension—Docetaxel—ovarian cancer	0.000384	0.000428	CcSEcCtD
Sibutramine—Haematuria—Doxorubicin—ovarian cancer	0.000383	0.000427	CcSEcCtD
Sibutramine—Abdominal pain—Paclitaxel—ovarian cancer	0.000383	0.000427	CcSEcCtD
Sibutramine—Body temperature increased—Paclitaxel—ovarian cancer	0.000383	0.000427	CcSEcCtD
Sibutramine—Epistaxis—Doxorubicin—ovarian cancer	0.000379	0.000422	CcSEcCtD
Sibutramine—Sinusitis—Doxorubicin—ovarian cancer	0.000377	0.00042	CcSEcCtD
Sibutramine—Visual impairment—Epirubicin—ovarian cancer	0.000376	0.000419	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000374	0.000417	CcSEcCtD
Sibutramine—Insomnia—Docetaxel—ovarian cancer	0.000371	0.000414	CcSEcCtD
Sibutramine—Paraesthesia—Docetaxel—ovarian cancer	0.000369	0.000411	CcSEcCtD
Sibutramine—Bradycardia—Doxorubicin—ovarian cancer	0.000367	0.000409	CcSEcCtD
Sibutramine—Dyspnoea—Docetaxel—ovarian cancer	0.000366	0.000408	CcSEcCtD
Sibutramine—Somnolence—Docetaxel—ovarian cancer	0.000365	0.000407	CcSEcCtD
Sibutramine—Eye disorder—Epirubicin—ovarian cancer	0.000364	0.000406	CcSEcCtD
Sibutramine—Tinnitus—Epirubicin—ovarian cancer	0.000363	0.000405	CcSEcCtD
Sibutramine—Haemoglobin—Doxorubicin—ovarian cancer	0.000362	0.000404	CcSEcCtD
Sibutramine—Rhinitis—Doxorubicin—ovarian cancer	0.000362	0.000403	CcSEcCtD
Sibutramine—Dyspepsia—Docetaxel—ovarian cancer	0.000361	0.000403	CcSEcCtD
Sibutramine—Haemorrhage—Doxorubicin—ovarian cancer	0.000361	0.000402	CcSEcCtD
Sibutramine—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000359	0.0004	CcSEcCtD
Sibutramine—Pharyngitis—Doxorubicin—ovarian cancer	0.000358	0.000399	CcSEcCtD
Sibutramine—Decreased appetite—Docetaxel—ovarian cancer	0.000357	0.000398	CcSEcCtD
Sibutramine—Hypersensitivity—Paclitaxel—ovarian cancer	0.000357	0.000398	CcSEcCtD
Sibutramine—Oedema peripheral—Doxorubicin—ovarian cancer	0.000355	0.000396	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000354	0.000395	CcSEcCtD
Sibutramine—Angiopathy—Epirubicin—ovarian cancer	0.000354	0.000394	CcSEcCtD
Sibutramine—Immune system disorder—Epirubicin—ovarian cancer	0.000352	0.000392	CcSEcCtD
Sibutramine—Constipation—Docetaxel—ovarian cancer	0.000351	0.000391	CcSEcCtD
Sibutramine—Pain—Docetaxel—ovarian cancer	0.000351	0.000391	CcSEcCtD
Sibutramine—Chills—Epirubicin—ovarian cancer	0.00035	0.00039	CcSEcCtD
Sibutramine—Arrhythmia—Epirubicin—ovarian cancer	0.000348	0.000388	CcSEcCtD
Sibutramine—Visual impairment—Doxorubicin—ovarian cancer	0.000348	0.000387	CcSEcCtD
Sibutramine—Asthenia—Paclitaxel—ovarian cancer	0.000347	0.000387	CcSEcCtD
Sibutramine—Alopecia—Epirubicin—ovarian cancer	0.000344	0.000384	CcSEcCtD
Sibutramine—Pruritus—Paclitaxel—ovarian cancer	0.000343	0.000382	CcSEcCtD
Sibutramine—Malnutrition—Epirubicin—ovarian cancer	0.000339	0.000378	CcSEcCtD
Sibutramine—Feeling abnormal—Docetaxel—ovarian cancer	0.000338	0.000377	CcSEcCtD
Sibutramine—Eye disorder—Doxorubicin—ovarian cancer	0.000337	0.000376	CcSEcCtD
Sibutramine—Tinnitus—Doxorubicin—ovarian cancer	0.000336	0.000375	CcSEcCtD
Sibutramine—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000336	0.000374	CcSEcCtD
Sibutramine—Flatulence—Epirubicin—ovarian cancer	0.000334	0.000373	CcSEcCtD
Sibutramine—Tension—Epirubicin—ovarian cancer	0.000333	0.000371	CcSEcCtD
Sibutramine—Dysgeusia—Epirubicin—ovarian cancer	0.000332	0.00037	CcSEcCtD
Sibutramine—Diarrhoea—Paclitaxel—ovarian cancer	0.000331	0.000369	CcSEcCtD
Sibutramine—Nervousness—Epirubicin—ovarian cancer	0.00033	0.000367	CcSEcCtD
Sibutramine—Back pain—Epirubicin—ovarian cancer	0.000328	0.000366	CcSEcCtD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—PARK2—ovarian cancer	0.000328	0.0284	CbGpPWpGaD
Sibutramine—Angiopathy—Doxorubicin—ovarian cancer	0.000327	0.000365	CcSEcCtD
Sibutramine—Muscle spasms—Epirubicin—ovarian cancer	0.000326	0.000364	CcSEcCtD
Sibutramine—Immune system disorder—Doxorubicin—ovarian cancer	0.000326	0.000363	CcSEcCtD
Sibutramine—Abdominal pain—Docetaxel—ovarian cancer	0.000325	0.000362	CcSEcCtD
Sibutramine—Body temperature increased—Docetaxel—ovarian cancer	0.000325	0.000362	CcSEcCtD
Sibutramine—Chills—Doxorubicin—ovarian cancer	0.000324	0.000361	CcSEcCtD
Sibutramine—Arrhythmia—Doxorubicin—ovarian cancer	0.000322	0.000359	CcSEcCtD
Sibutramine—Dizziness—Paclitaxel—ovarian cancer	0.00032	0.000357	CcSEcCtD
Sibutramine—Vision blurred—Epirubicin—ovarian cancer	0.00032	0.000356	CcSEcCtD
Sibutramine—Alopecia—Doxorubicin—ovarian cancer	0.000319	0.000355	CcSEcCtD
Sibutramine—Ill-defined disorder—Epirubicin—ovarian cancer	0.000315	0.000351	CcSEcCtD
Sibutramine—Malnutrition—Doxorubicin—ovarian cancer	0.000314	0.00035	CcSEcCtD
Sibutramine—Anaemia—Epirubicin—ovarian cancer	0.000314	0.00035	CcSEcCtD
Sibutramine—Agitation—Epirubicin—ovarian cancer	0.000312	0.000348	CcSEcCtD
Sibutramine—Flatulence—Doxorubicin—ovarian cancer	0.000309	0.000345	CcSEcCtD
Sibutramine—Tension—Doxorubicin—ovarian cancer	0.000308	0.000343	CcSEcCtD
Sibutramine—Vomiting—Paclitaxel—ovarian cancer	0.000308	0.000343	CcSEcCtD
Sibutramine—Dysgeusia—Doxorubicin—ovarian cancer	0.000307	0.000343	CcSEcCtD
Sibutramine—Malaise—Epirubicin—ovarian cancer	0.000306	0.000341	CcSEcCtD
Sibutramine—Rash—Paclitaxel—ovarian cancer	0.000305	0.00034	CcSEcCtD
Sibutramine—Dermatitis—Paclitaxel—ovarian cancer	0.000305	0.00034	CcSEcCtD
Sibutramine—Nervousness—Doxorubicin—ovarian cancer	0.000305	0.00034	CcSEcCtD
Sibutramine—Vertigo—Epirubicin—ovarian cancer	0.000305	0.00034	CcSEcCtD
Sibutramine—Syncope—Epirubicin—ovarian cancer	0.000304	0.000339	CcSEcCtD
Sibutramine—Leukopenia—Epirubicin—ovarian cancer	0.000304	0.000339	CcSEcCtD
Sibutramine—Back pain—Doxorubicin—ovarian cancer	0.000304	0.000339	CcSEcCtD
Sibutramine—Headache—Paclitaxel—ovarian cancer	0.000303	0.000338	CcSEcCtD
Sibutramine—Hypersensitivity—Docetaxel—ovarian cancer	0.000302	0.000337	CcSEcCtD
Sibutramine—Muscle spasms—Doxorubicin—ovarian cancer	0.000302	0.000336	CcSEcCtD
Sibutramine—Palpitations—Epirubicin—ovarian cancer	0.0003	0.000334	CcSEcCtD
Sibutramine—Loss of consciousness—Epirubicin—ovarian cancer	0.000298	0.000332	CcSEcCtD
Sibutramine—Cough—Epirubicin—ovarian cancer	0.000296	0.00033	CcSEcCtD
Sibutramine—Vision blurred—Doxorubicin—ovarian cancer	0.000296	0.00033	CcSEcCtD
Sibutramine—Asthenia—Docetaxel—ovarian cancer	0.000295	0.000328	CcSEcCtD
Sibutramine—Convulsion—Epirubicin—ovarian cancer	0.000294	0.000328	CcSEcCtD
Sibutramine—Hypertension—Epirubicin—ovarian cancer	0.000293	0.000327	CcSEcCtD
Sibutramine—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000291	0.000325	CcSEcCtD
Sibutramine—Pruritus—Docetaxel—ovarian cancer	0.00029	0.000324	CcSEcCtD
Sibutramine—Anaemia—Doxorubicin—ovarian cancer	0.00029	0.000323	CcSEcCtD
Sibutramine—Arthralgia—Epirubicin—ovarian cancer	0.000289	0.000322	CcSEcCtD
Sibutramine—Chest pain—Epirubicin—ovarian cancer	0.000289	0.000322	CcSEcCtD
Sibutramine—Myalgia—Epirubicin—ovarian cancer	0.000289	0.000322	CcSEcCtD
Sibutramine—Agitation—Doxorubicin—ovarian cancer	0.000288	0.000322	CcSEcCtD
Sibutramine—Anxiety—Epirubicin—ovarian cancer	0.000288	0.000321	CcSEcCtD
Sibutramine—Nausea—Paclitaxel—ovarian cancer	0.000288	0.000321	CcSEcCtD
Sibutramine—Discomfort—Epirubicin—ovarian cancer	0.000285	0.000318	CcSEcCtD
Sibutramine—Malaise—Doxorubicin—ovarian cancer	0.000283	0.000316	CcSEcCtD
Sibutramine—Dry mouth—Epirubicin—ovarian cancer	0.000282	0.000315	CcSEcCtD
Sibutramine—Vertigo—Doxorubicin—ovarian cancer	0.000282	0.000314	CcSEcCtD
Sibutramine—Syncope—Doxorubicin—ovarian cancer	0.000282	0.000314	CcSEcCtD
Sibutramine—Leukopenia—Doxorubicin—ovarian cancer	0.000281	0.000313	CcSEcCtD
Sibutramine—Diarrhoea—Docetaxel—ovarian cancer	0.000281	0.000313	CcSEcCtD
Sibutramine—Confusional state—Epirubicin—ovarian cancer	0.000279	0.000311	CcSEcCtD
Sibutramine—Palpitations—Doxorubicin—ovarian cancer	0.000277	0.000309	CcSEcCtD
Sibutramine—Oedema—Epirubicin—ovarian cancer	0.000277	0.000309	CcSEcCtD
Sibutramine—Anaphylactic shock—Epirubicin—ovarian cancer	0.000277	0.000309	CcSEcCtD
Sibutramine—Loss of consciousness—Doxorubicin—ovarian cancer	0.000276	0.000308	CcSEcCtD
Sibutramine—Infection—Epirubicin—ovarian cancer	0.000275	0.000307	CcSEcCtD
Sibutramine—Cough—Doxorubicin—ovarian cancer	0.000274	0.000305	CcSEcCtD
Sibutramine—Shock—Epirubicin—ovarian cancer	0.000272	0.000304	CcSEcCtD
Sibutramine—Convulsion—Doxorubicin—ovarian cancer	0.000272	0.000303	CcSEcCtD
Sibutramine—Dizziness—Docetaxel—ovarian cancer	0.000271	0.000303	CcSEcCtD
Sibutramine—Thrombocytopenia—Epirubicin—ovarian cancer	0.000271	0.000302	CcSEcCtD
Sibutramine—Hypertension—Doxorubicin—ovarian cancer	0.000271	0.000302	CcSEcCtD
Sibutramine—Tachycardia—Epirubicin—ovarian cancer	0.00027	0.000301	CcSEcCtD
Sibutramine—Skin disorder—Epirubicin—ovarian cancer	0.000269	0.0003	CcSEcCtD
Sibutramine—Hyperhidrosis—Epirubicin—ovarian cancer	0.000268	0.000298	CcSEcCtD
Sibutramine—Chest pain—Doxorubicin—ovarian cancer	0.000267	0.000298	CcSEcCtD
Sibutramine—Arthralgia—Doxorubicin—ovarian cancer	0.000267	0.000298	CcSEcCtD
Sibutramine—Myalgia—Doxorubicin—ovarian cancer	0.000267	0.000298	CcSEcCtD
Sibutramine—Anxiety—Doxorubicin—ovarian cancer	0.000266	0.000297	CcSEcCtD
Sibutramine—Discomfort—Doxorubicin—ovarian cancer	0.000264	0.000294	CcSEcCtD
Sibutramine—Anorexia—Epirubicin—ovarian cancer	0.000264	0.000294	CcSEcCtD
Sibutramine—Dry mouth—Doxorubicin—ovarian cancer	0.000261	0.000291	CcSEcCtD
Sibutramine—Vomiting—Docetaxel—ovarian cancer	0.000261	0.000291	CcSEcCtD
Sibutramine—Rash—Docetaxel—ovarian cancer	0.000259	0.000289	CcSEcCtD
Sibutramine—Hypotension—Epirubicin—ovarian cancer	0.000259	0.000288	CcSEcCtD
Sibutramine—Dermatitis—Docetaxel—ovarian cancer	0.000259	0.000288	CcSEcCtD
Sibutramine—Confusional state—Doxorubicin—ovarian cancer	0.000258	0.000288	CcSEcCtD
Sibutramine—Headache—Docetaxel—ovarian cancer	0.000257	0.000287	CcSEcCtD
Sibutramine—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000256	0.000286	CcSEcCtD
Sibutramine—Oedema—Doxorubicin—ovarian cancer	0.000256	0.000286	CcSEcCtD
Sibutramine—Infection—Doxorubicin—ovarian cancer	0.000255	0.000284	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000252	0.000281	CcSEcCtD
Sibutramine—Shock—Doxorubicin—ovarian cancer	0.000252	0.000281	CcSEcCtD
Sibutramine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000251	0.00028	CcSEcCtD
Sibutramine—Insomnia—Epirubicin—ovarian cancer	0.00025	0.000279	CcSEcCtD
Sibutramine—Tachycardia—Doxorubicin—ovarian cancer	0.00025	0.000279	CcSEcCtD
Sibutramine—Skin disorder—Doxorubicin—ovarian cancer	0.000249	0.000277	CcSEcCtD
Sibutramine—Paraesthesia—Epirubicin—ovarian cancer	0.000249	0.000277	CcSEcCtD
Sibutramine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000248	0.000276	CcSEcCtD
Sibutramine—Dyspnoea—Epirubicin—ovarian cancer	0.000247	0.000275	CcSEcCtD
Sibutramine—Somnolence—Epirubicin—ovarian cancer	0.000246	0.000274	CcSEcCtD
Sibutramine—Anorexia—Doxorubicin—ovarian cancer	0.000244	0.000272	CcSEcCtD
Sibutramine—Nausea—Docetaxel—ovarian cancer	0.000244	0.000272	CcSEcCtD
Sibutramine—Dyspepsia—Epirubicin—ovarian cancer	0.000244	0.000272	CcSEcCtD
Sibutramine—Decreased appetite—Epirubicin—ovarian cancer	0.000241	0.000268	CcSEcCtD
Sibutramine—Hypotension—Doxorubicin—ovarian cancer	0.000239	0.000267	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000239	0.000267	CcSEcCtD
Sibutramine—Constipation—Epirubicin—ovarian cancer	0.000237	0.000264	CcSEcCtD
Sibutramine—Pain—Epirubicin—ovarian cancer	0.000237	0.000264	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000233	0.00026	CcSEcCtD
Sibutramine—Insomnia—Doxorubicin—ovarian cancer	0.000232	0.000258	CcSEcCtD
Sibutramine—Paraesthesia—Doxorubicin—ovarian cancer	0.00023	0.000256	CcSEcCtD
Sibutramine—Dyspnoea—Doxorubicin—ovarian cancer	0.000228	0.000255	CcSEcCtD
Sibutramine—Feeling abnormal—Epirubicin—ovarian cancer	0.000228	0.000254	CcSEcCtD
Sibutramine—Somnolence—Doxorubicin—ovarian cancer	0.000228	0.000254	CcSEcCtD
Sibutramine—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000226	0.000252	CcSEcCtD
Sibutramine—Dyspepsia—Doxorubicin—ovarian cancer	0.000226	0.000251	CcSEcCtD
Sibutramine—CYP3A4—Liver X Receptor Pathway—FASN—ovarian cancer	0.000224	0.0194	CbGpPWpGaD
Sibutramine—Decreased appetite—Doxorubicin—ovarian cancer	0.000223	0.000248	CcSEcCtD
Sibutramine—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—ovarian cancer	0.000222	0.0192	CbGpPWpGaD
Sibutramine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000221	0.000247	CcSEcCtD
Sibutramine—Urticaria—Epirubicin—ovarian cancer	0.00022	0.000245	CcSEcCtD
Sibutramine—Pain—Doxorubicin—ovarian cancer	0.000219	0.000244	CcSEcCtD
Sibutramine—Constipation—Doxorubicin—ovarian cancer	0.000219	0.000244	CcSEcCtD
Sibutramine—Abdominal pain—Epirubicin—ovarian cancer	0.000219	0.000244	CcSEcCtD
Sibutramine—Body temperature increased—Epirubicin—ovarian cancer	0.000219	0.000244	CcSEcCtD
Sibutramine—Feeling abnormal—Doxorubicin—ovarian cancer	0.000211	0.000235	CcSEcCtD
Sibutramine—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000209	0.000234	CcSEcCtD
Sibutramine—Hypersensitivity—Epirubicin—ovarian cancer	0.000204	0.000227	CcSEcCtD
Sibutramine—Urticaria—Doxorubicin—ovarian cancer	0.000204	0.000227	CcSEcCtD
Sibutramine—Abdominal pain—Doxorubicin—ovarian cancer	0.000203	0.000226	CcSEcCtD
Sibutramine—Body temperature increased—Doxorubicin—ovarian cancer	0.000203	0.000226	CcSEcCtD
Sibutramine—CYP3A4—Codeine and Morphine Metabolism—ABCB1—ovarian cancer	0.000201	0.0174	CbGpPWpGaD
Sibutramine—Asthenia—Epirubicin—ovarian cancer	0.000199	0.000221	CcSEcCtD
Sibutramine—Pruritus—Epirubicin—ovarian cancer	0.000196	0.000218	CcSEcCtD
Sibutramine—Diarrhoea—Epirubicin—ovarian cancer	0.000189	0.000211	CcSEcCtD
Sibutramine—Hypersensitivity—Doxorubicin—ovarian cancer	0.000189	0.00021	CcSEcCtD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—CCNE1—ovarian cancer	0.000189	0.0163	CbGpPWpGaD
Sibutramine—Asthenia—Doxorubicin—ovarian cancer	0.000184	0.000205	CcSEcCtD
Sibutramine—Dizziness—Epirubicin—ovarian cancer	0.000183	0.000204	CcSEcCtD
Sibutramine—SLC6A4—Circadian rythm related genes—TOP1—ovarian cancer	0.000182	0.0158	CbGpPWpGaD
Sibutramine—Pruritus—Doxorubicin—ovarian cancer	0.000181	0.000202	CcSEcCtD
Sibutramine—Vomiting—Epirubicin—ovarian cancer	0.000176	0.000196	CcSEcCtD
Sibutramine—Diarrhoea—Doxorubicin—ovarian cancer	0.000175	0.000195	CcSEcCtD
Sibutramine—Rash—Epirubicin—ovarian cancer	0.000175	0.000195	CcSEcCtD
Sibutramine—Dermatitis—Epirubicin—ovarian cancer	0.000174	0.000194	CcSEcCtD
Sibutramine—Headache—Epirubicin—ovarian cancer	0.000173	0.000193	CcSEcCtD
Sibutramine—Dizziness—Doxorubicin—ovarian cancer	0.000169	0.000189	CcSEcCtD
Sibutramine—Nausea—Epirubicin—ovarian cancer	0.000164	0.000183	CcSEcCtD
Sibutramine—Vomiting—Doxorubicin—ovarian cancer	0.000163	0.000182	CcSEcCtD
Sibutramine—Rash—Doxorubicin—ovarian cancer	0.000162	0.00018	CcSEcCtD
Sibutramine—Dermatitis—Doxorubicin—ovarian cancer	0.000161	0.00018	CcSEcCtD
Sibutramine—Headache—Doxorubicin—ovarian cancer	0.00016	0.000179	CcSEcCtD
Sibutramine—SLC6A4—Circadian rythm related genes—PPP1CC—ovarian cancer	0.000159	0.0138	CbGpPWpGaD
Sibutramine—Nausea—Doxorubicin—ovarian cancer	0.000152	0.00017	CcSEcCtD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—NSF—ovarian cancer	0.000143	0.0124	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—HNF1B—ovarian cancer	0.000138	0.012	CbGpPWpGaD
Sibutramine—CYP3A4—Estrogen metabolism—CYP1B1—ovarian cancer	0.000127	0.011	CbGpPWpGaD
Sibutramine—CYP3A4—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000113	0.00976	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—SLC5A5—ovarian cancer	0.000111	0.00958	CbGpPWpGaD
Sibutramine—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—ovarian cancer	0.00011	0.00952	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—NSF—ovarian cancer	0.00011	0.0095	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—SLC2A1—ovarian cancer	0.000107	0.00925	CbGpPWpGaD
Sibutramine—SLC6A3—Dopaminergic Neurogenesis—STAT3—ovarian cancer	9.72e-05	0.00842	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—CASP3—ovarian cancer	9.58e-05	0.0083	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—SLC5A5—ovarian cancer	9.51e-05	0.00824	CbGpPWpGaD
Sibutramine—CYP3A4—Irinotecan Pathway—APC—ovarian cancer	9.25e-05	0.00801	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—SLC2A1—ovarian cancer	9.18e-05	0.00795	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—SLC5A5—ovarian cancer	8.42e-05	0.0073	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—SLC2A1—ovarian cancer	8.14e-05	0.00705	CbGpPWpGaD
Sibutramine—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	6.63e-05	0.00574	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—TYMS—ovarian cancer	6.41e-05	0.00555	CbGpPWpGaD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	6.31e-05	0.00547	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—AQP3—ovarian cancer	6.02e-05	0.00522	CbGpPWpGaD
Sibutramine—CYP3A4—Tryptophan metabolism—CYP1B1—ovarian cancer	6.02e-05	0.00521	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	5.99e-05	0.00519	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	5.79e-05	0.00501	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ATP7B—ovarian cancer	5.77e-05	0.005	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—AQP3—ovarian cancer	5.34e-05	0.00462	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—ovarian cancer	5.31e-05	0.0046	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC2A1—ovarian cancer	5.13e-05	0.00444	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ATP7B—ovarian cancer	5.12e-05	0.00443	CbGpPWpGaD
Sibutramine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	4.87e-05	0.00421	CbGpPWpGaD
Sibutramine—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	4.8e-05	0.00416	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—TUBB3—ovarian cancer	4.56e-05	0.00395	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	4.25e-05	0.00368	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—CASP3—ovarian cancer	4.06e-05	0.00352	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—TUBB3—ovarian cancer	4.04e-05	0.0035	CbGpPWpGaD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	3.94e-05	0.00342	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	3.92e-05	0.00339	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	3.45e-05	0.00299	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—PTEN—ovarian cancer	3.12e-05	0.0027	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	3.05e-05	0.00264	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.94e-05	0.00255	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	2.7e-05	0.00234	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.61e-05	0.00226	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—IL6—ovarian cancer	2.38e-05	0.00206	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	2.32e-05	0.00201	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—TP53—ovarian cancer	2.13e-05	0.00184	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	2.1e-05	0.00181	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	2.07e-05	0.00179	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ABCB1—ovarian cancer	2.06e-05	0.00178	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—IL6—ovarian cancer	1.95e-05	0.00169	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—MAPK1—ovarian cancer	1.94e-05	0.00168	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—HRAS—ovarian cancer	1.56e-05	0.00135	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—MAPK1—ovarian cancer	1.48e-05	0.00129	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—NME2—ovarian cancer	1.28e-05	0.00111	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—HRAS—ovarian cancer	1.19e-05	0.00103	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYTB—ovarian cancer	8.23e-06	0.000713	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PPP1CC—ovarian cancer	7.2e-06	0.000623	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—BRIP1—ovarian cancer	7.2e-06	0.000623	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—YAP1—ovarian cancer	4.83e-06	0.000418	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—FASN—ovarian cancer	3.93e-06	0.000341	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SLC5A5—ovarian cancer	3.87e-06	0.000335	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SLC2A1—ovarian cancer	3.74e-06	0.000324	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYP1B1—ovarian cancer	3.58e-06	0.00031	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	3.18e-06	0.000275	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ABCB1—ovarian cancer	2.95e-06	0.000256	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—TYMS—ovarian cancer	2.9e-06	0.000251	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CAV1—ovarian cancer	2.34e-06	0.000202	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.13e-06	0.000184	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.87e-06	0.000162	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.63e-06	0.000141	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PTEN—ovarian cancer	1.41e-06	0.000122	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PIK3CA—ovarian cancer	9.94e-07	8.6e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—AKT1—ovarian cancer	8.12e-07	7.03e-05	CbGpPWpGaD
